Hyperthermia for treatment of rectal cancer: evaluation for induction of multidrug resistance gene (mdr1) expression

Int J Cancer. 1999 Jan 5;80(1):5-12. doi: 10.1002/(sici)1097-0215(19990105)80:1<5::aid-ijc2>3.0.co;2-f.

Abstract

Environmental stress factors, such as heat, may induce multidrug resistance gene (mdr1) expression, which could result in the disadvantageous multidrug resistance (MDR) phenotype. To evaluate this possibility in a clinical situation, we investigated mdr1 gene expression in patients with locally advanced rectal cancer who underwent preoperative radio-chemo-thermo-therapy (RCTT). Patients were classified into groups according to the treatment schedule of RCTT vs. radio-chemo-therapy (RCT) without hyperthermia (control group). Expression of the mdr1 gene was analyzed in tumors and normal rectal tissues prior to and post-treatment (RCTT or RCT, respectively) by means of semi-quantitative and quantitative reverse transcription-polymerase chain reaction (RT-PCR). The data were correlated with therapeutic response and survival parameters. Based on our evaluation criteria, in 2 of 19 tumors of the RCTT group, mdr1 gene expression was increased more than 2-fold; in 3 of 19 tumors of this group, however, mdr1 expression was decreased more than 2-fold. In the patient control group, levels of mdr1 gene expression were reduced in 2 of 8 tumors. Thus, hyperthermia combined with RCT (RCTT) in comparison with RCT alone does not lead to an increase in mdr1 gene expression in patients with locally advanced rectal cancer within the preoperative treatment schedule. The risk of inducing the classical multidrug resistance phenotype by hyperthermia was thus minimal in this clinical setting. Subsequent adjuvant chemotherapy should thus not be hindered.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics
  • Antimetabolites, Antineoplastic / therapeutic use
  • Combined Modality Therapy
  • Disease-Free Survival
  • Dose Fractionation, Radiation
  • Drug Resistance, Multiple / genetics*
  • Fluorouracil / therapeutic use
  • Follow-Up Studies
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Hyperthermia, Induced*
  • Leucovorin / therapeutic use
  • Prognosis
  • Rectal Neoplasms / drug therapy
  • Rectal Neoplasms / genetics
  • Rectal Neoplasms / radiotherapy
  • Rectal Neoplasms / surgery
  • Rectal Neoplasms / therapy*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Survival Analysis
  • Time Factors

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Antimetabolites, Antineoplastic
  • Leucovorin
  • Fluorouracil